BridgeBio Oncology Therapeutics (BBOT) Other Non Operating Income (2025 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Other Non Operating Income of -$94000.0 for Q1 2026, down 1075.0% sequentially from -$8000.0 in Q4 2025, and down 4600.0% YoY from $2088.9 in Q1 2025.
Powered by 
Analysis
BridgeBio Oncology Therapeutics (BBOT) Other Non Operating Income (2025 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Other Non Operating Income for 2 years, with the latest figure at -$94000.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 4600.0% year-over-year to -$94000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$134000.0 (changed N/A YoY) and the FY2025 annual result came in at -$35000.0, changed N/A from the prior year.
- Other Non Operating Income slipped to -$94000.0 in Q1 2026 per BBOT's latest filing, from -$8000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at -$2000.0 in Q1 2025 and troughed at -$94000.0 in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn |
| 10 | BridgeBio Oncology Therapeutics | 719.69 Mn | 493.97 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14,000.00 |
| Mar 31, 2026 | -94,000.00 |
| Dec 31, 2025 | 5,000.00 |
| Sep 30, 2025 | -30,000.00 |
| Jun 30, 2025 | -8,000.00 |
| Mar 31, 2025 | -2,000.00 |